Department of Pediatrics
Adoptive cell therapy for the treatment of pediatric cancers and mitigation of graft versus host disease
We focus on development of cell-based therapies including NK cells and CAR T cells, for immunotherapy of childhood cancers. The laboratory is also developing alternatively activated macrophages to treat complications of hematopoietic stem cell transplant like graft-versus-host-disease and acute radiation syndrome. In the clinic, Dr. Capitini is a site Principal Investigator for CAR T-cell trials for tisagenlecleucel (Kymriah), which was FDA-approved in 2017 for the treatment of relapsed/refractory B cell leukemia.